Table 1.
Participant characteristics by HIV serostatus.
| Overall | HIV+KS | HIV−KS | P | |
| N = 200 | N = 166 | N = 34 | ||
| Male, N (%) | 156 (78) | 127 (76.5) | 29 (85.3) | 0.26 |
| Age, median (range) | 34 (18, 90) | 32 (18, 75) | 46 (19, 90) | <0.001 |
| ACTG stage, N (%) | ||||
| T1 | 176 (88) | 144 (86.7) | 32 (94.1) | 0.23 |
| I1 | 93 (56.4) | |||
| S1 | 147 (73.5) | 124 (74.7) | 23 (67.6) | 0.40 |
| Karnofsky <70, N (%) | 58 (29) | 47 (28.3) | 11 (32.4) | 0.64 |
| B-symptoms, N (%) | 138 (69) | 118 (71.1) | 20 (58.8) | 0.16 |
| Opportunistic infections, N (%) | 29 (14.5) | 27 (16.3) | 2 (5.9) | 0.12 |
| BMI (kg/m2), median (IRQ)a | 26 (14.1) | 21.5 (19.8, 23.3) | 21.7 (19.7, 23.9) | 0.44 |
| Hemoglobin, median (IQR)a | 10.3 (8.9, 12.5) | 10 (8.7, 11.9) | 12.8 (11.1, 14.9) | <0.001 |
| Platelets, median (IQR)a | 232 (155, 297) | 223 (138, 297) | 245.5 (199, 305) | 0.08 |
| Abnormal chest X-ray finding, N (%)a,b | 65 (38.7) | 61 (43.9) | 4 (13.7) | 0.002 |
| Months since first KS lesion, median (IQR)a | 7 (3, 17) | 6 (3, 12) | 22 (8, 48) | <0.001 |
| Distinct sites with KS lesions | 5 (2, 7) | 5 (3, 7) | 2 (1, 3) | <0.001 |
| Any edema, N (%) | 165 (82.5) | 135 (81.3) | 30 (88.2) | 0.33 |
| Any macular lesions, N (%) | 195 (97.5) | 162 (97.6) | 33 (97.1) | 0.86 |
| Any nodular lesions, N (%) | 134 (67) | 107 (64.5) | 27 (79.4) | 0.09 |
| Any fungating lesions, N (%) | 93 (46.5) | 70 (42.2) | 23 (67.7) | 0.007 |
| Months since HIV diagnosis, median (IQR)a | 2 (1, 5) | |||
| HIV viral load, log10(copies/ml) median (IQR)c | 5.3 (4.9, 5.7) | |||
| CD4+ count, median (IQR) | 167 (49, 338) | |||
| KSHV detected in plasma, N (%)a | 188 (95.4) | 158 (96.3) | 30 (90.9) | 0.17 |
| Plasma KSHV titer, log10(copies/ml), median (IQR)d | 4 (3.6, 4.5) | 4.1 (3.7, 4.5) | 3.8 (3.1, 4) | <0.001 |
| KSHV detected in oral swaba, N (%) | 115 (57.8) | 101 (61.2) | 14 (41.2) | 0.03 |
| Oral KSHV titer log10(copies/ml), median (IQR)e | 3.6 (2.9, 4.5) | 3.6 (2.9, 4.5) | 3.3 (2.6, 5.1) | 0.80 |
ACTG, AIDS Clinical Trials Group; IQR, interquartile range; KHSV, Kaposi sarcoma-associated herpesvirus; KS, Kaposi sarcoma.
a
Percentages, medians, ranges, and P-values exclude participants missing data (Table 1, Supplemental Digital Content).
b
Infiltrate or effusion, unilateral or bilateral.
c
Excludes one participant for whom viral load was not assessed, and two participants with undetectable viral load.
d
Among participants with detectable plasma KSHV.
e
Among participants with detectable oral KSHV.